植入式心电记录仪诊断获益随时间变化:Brugada综合征例外
本研究回顾性分析意大利5个中心1734例因不明原因晕厥、心悸、隐源性卒中或Brugada综合征植入ILR的患者,中位随访34个月。诊断获益与治疗影响随植入适应证不同而差异显著,晕厥和心悸的可干预诊断集中于早期,隐源性卒中后期发现房颤仍可改变抗栓管理,Brugada综合征则持续检出室速和有临床意义的停搏。结果支持按适应证驱动监测与再植入策略,而非仅依据设备寿命统一管理。
要点
- 晕厥和心悸的可干预诊断主要集中在ILR植入后早期,26个月后诊断效率明显下降。
- 隐源性卒中后期检出房颤仍可能改变抗栓管理,需个体化延长监测。
- Brugada综合征在长期随访中持续检出室速和显著停搏,支持延长监测。
核心结论
- ILR诊断获益与治疗影响随植入适应证不同而显著差异,支持按适应证驱动的监测和再植入策略。
研究设计与样本
- 回顾性分析意大利5个中心1734例因不明原因晕厥、心悸、隐源性卒中或Brugada综合征接受ILR植入的连续患者,中位随访34个月。
主要发现
- 以26个月为整体早期与晚期诊断分界,适应证特异性最佳诊断窗口为晕厥14个月、心悸13个月、隐源性卒中16个月、Brugada综合征55个月。
- 晕厥和心悸的可干预诊断多发生在早期,26个月后诊断效率显著下降,晚期发现常与初始表现关联不明确。
- 隐源性卒中的房颤检出早期最频繁,但后期检出仍可改变抗栓管理,支持个体化延长监测策略。
- Brugada综合征在长期随访中持续检出室速和有临床意义的停搏,需延长随访监测。
关键数值与推荐
- 晕厥的目标诊断为停搏,心悸为室上性心动过速或房颤,隐源性卒中的目标诊断为房颤,Brugada综合征为室速或停搏。
临床怎么用
- 晕厥和心悸患者可考虑较短监测期,隐源性卒中需个体化延长监测,Brugada综合征应延长监测周期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnostic yield and therapeutic impact varied substantially according to the indication for implantation. Actionable diagnoses were concentrated in the early follow-up period for syncope and palpitations, whereas late atrial fibrillation detection after cryptogenic stroke could still modify antithrombotic management. In contrast, patients with Brugada syndrome showed sustained detection of ventricular tachycardia and clinically significant pauses over prolonged follow-up, supporting extended surveillance. These findings favor indication-driven monitoring and reimplantation strategies rather than a uniform approach based on device longevity alone. ABSTRACT Introduction The optimal duration of implantable loop recorder (ILR) monitoring remains uncertain and may differ according to the indication for implantation. We evaluated whether the time-dependent diagnostic yield and clinical relevance of ILR-detected arrhythmias differ among patients implanted for syncope, palpitations, cryptogenic stroke, or Brugada syndrome. Objective This study sought to define the time-dependent diagnostic yield of ILRs across clinical indications and to assess whether early and late diagnoses differed in their impact on clinical management. Methods and Results We retrospectively analyzed 1734 consecutive patients undergoing ILR implantation at 5 Italian centers for unexplained syncope, palpitations, cryptogenic stroke, or Brugada syndrome. Diagnosis of interest was defined according to the implant indication: pauses for syncope, supraventricular tachycardia or atrial fibrillation for palpitations, atrial fibrillation for cryptogenic stroke, and ventricular tachycardia or pauses for Brugada syndrome. Median follow-up was 34 months. Maximally selected rank statistics identified 26 months as the global threshold separating early from late diagnoses, while indication-specific optimal diagnostic windows were 14 months for syncope, 13 months for palpitations, 16 months for cryptogenic stroke, and 55 months for Brugada syndrome. In syncope and palpitations, most actionable diagnoses occurred early, and diagnostic efficiency declined markedly after 26 months, with late findings often less clearly related to the index presentation. In cryptogenic stroke, atrial fibrillation detection was most frequent early but could still lead to changes in antithrombotic management later, supporting an individualized “gray-zone” approach to prolonged monitoring. By contrast, Brugada syndrome showed sus
引用
- Journal of Cardiovascular Electrophysiology:Time‐Dependent Diagnostic Yield and Therapeutic Impact of Implantable Loop Recorders, Brugada Syndrome as the Exception
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。